In contrast, high AKT phosphorylation in IR MCL cell lines was sustained in the presence of ibrutinib treatment, suggesting a mechanism of bypassing the effect of ibrutinib to promote activation of the PI3K-AKT-mTOR axis. The gene discussed is AKT1; the disease is mantle cell lymphoma.